The lung adenocarcinoma patient (11) harboring dual DCTN1–ALK and ALK-CLIP4 rearrangements showed PR to crizotinib with a 12-month progression-free survival (PFS) and received alectinib as second-line treatment. This evidence concerns the gene ALK and lung adenocarcinoma.